Lisata Therapeutics (LSTA) news
Recent news
Lisata cuts ~72% of full-time workforce
AInvest Wire · Aug 4, 2026Lisata Therapeutics filed suit against KuvA Labs Inc
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has filed a lawsuit against Kuva Labs Inc. following the termination of their proposed merger agreement. The termination occurred on July 24, 2026, after Kuva Labs failed to secure the necessary financing to complete the transaction and accept tendered…
AInvest Wire · Aug 4, 2026Lisata Therapeutics - eliminates executive vice president of R&D and chief medical officer position
AInvest Wire · Aug 4, 2026Lisata Therapeutics - implements reduction in force of about 72% of full-time employees
AInvest Wire · Aug 4, 2026Lisata Therapeutics - board continues to evaluate strategic alternatives to enhance stockholder value
Lisata Therapeutics, Inc. (Nasdaq: LSTA) continues to evaluate strategic alternatives to enhance stockholder value, as part of its ongoing efforts to optimize corporate performance and long-term growth. The company, a clinical-stage pharmaceutical firm focused on developing therapies for advanced…
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.